The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study

Information on the long‐term prognosis of nonalcoholic fatty liver disease (NAFLD) is limited. We sought to describe the long‐term morbidity and mortality of patients with NAFLD with advanced fibrosis or cirrhosis by prospectively studying 247 such patients from four international centers (in Australia, USA, UK and Italy). Their natural history was then compared with 264 patients with HCV infection who were either naïve or non‐responders to treatment. Both cohorts were Child‐Pugh class A and had advanced fibrosis (stage 3) or cirrhosis (stage 4) confirmed by liver biopsy at enrollment. In the NAFLD cohort, followed up for a mean of 85.6 months (range, 6‐297), there were 48 (19.4%) liver‐related complications and 33 (13.4%) deaths or liver transplants. In the HCV cohort, followed up for 74.9 months (mean; range, 6‐238), there were 47 (16.7%) liver‐related complications and 25 (9.4%) deaths or liver transplants. When adjusting for baseline differences in age and gender, the cumulative incidence of liver‐related complications was lower in the NAFLD than the HCV cohort (P = 0.03), including incident hepatocellular cancer (6 versus 18; P = 0.03), but that of cardiovascular events (P = 0.17) and overall mortality (P = 0.6) were similar in both groups. In the NAFLD cohort, platelet count, stage 4 fibrosis, lowered platelet count, and lowered serum cholesterol and alanine aminotrasferase (ALT) levels were associated with liver‐related complications; an aspartate aminotransferase/ALT ratio >1 and older age were associated with overall mortality, and higher serum bilirubin levels and stage 4 fibrosis were associated with liver‐related mortality. Conclusions: Patients with NAFLD with advanced fibrosis or cirrhosis have lower rates of liver‐related complications and hepatocellular cancer than corresponding patients with HCV infection, but similar overall mortality. Some clinical and laboratory features predict liver‐related complications and other outcomes in patients with NAFLD. (HEPATOLOGY 2011;54:1208–1216)

[1]  R O Morgan,et al.  Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study , 2005, Gut.

[2]  Sang-hun Park.  Expanding the Natural History of Nonalcoholic Steatohepatitis: from Cryptogenic Cirrhosis to Hepatocellular Carcinoma , 2003 .

[3]  E. Brunt.  Nonalcoholic Steatohepatitis: Definition and Pathology , 2001, Seminars in liver disease.

[4]  P. Angulo.  Long‐term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? , 2010, Hepatology.

[5]  S. Caldwell,et al.  Epidemiology and natural history of non-alcoholic steatohepatitis. , 2009, Clinics in liver disease.

[6]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[7]  Robert A Fisher,et al.  Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C , 2006, Hepatology.

[8]  R. Hanson,et al.  The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.

[9]  Per Christoffersen,et al.  Final results of a long-term, clinical follow-up in fatty liver patients , 2009, Scandinavian journal of gastroenterology.

[10]  C. Day.  Natural history of NAFLD: remarkably benign in the absence of cirrhosis. , 2005, Gastroenterology.

[11]  M. Knuiman,et al.  NAFLD as a Risk Factor for the Development of Diabetes and the Metabolic Syndrome: An Eleven-Year Follow-up Study , 2009, The American Journal of Gastroenterology.

[12]  S. Sanderson,et al.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.

[13]  C. Day,et al.  Benefits of lifestyle modification in NAFLD , 2007, Gut.

[14]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[15]  Randall G. Lee,et al.  Nonalcoholic steatohepatitis: a study of 49 patients. , 1989, Human pathology.

[16]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[17]  S. Harrison,et al.  Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection , 2010, Hepatology.

[18]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[19]  P. Bedossa,et al.  Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C , 1994 .

[20]  M. Bennett,et al.  The natural history of nonalcoholic fatty liver: A follow‐up study , 1995, Hepatology.

[21]  M. Sorrell,et al.  Hepatocellular carcinoma , 1999, The Lancet.

[22]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[23]  J. Benson,et al.  The natural history of non-alcoholic fatty liver disease , 2006 .

[24]  P. Angulo.  GI Epidemiology: nonalcoholic fatty liver disease , 2007, Alimentary pharmacology & therapeutics.

[25]  C. Day.  Non-alcoholic fatty liver disease: current concepts and management strategies. , 2006, Clinical medicine.

[26]  D. Harnois,et al.  Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease , 2011 .

[27]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[28]  N. Bhala,et al.  Non-alcoholic fatty liver disease , 2009, BMJ : British Medical Journal.

[29]  K. Lindor,et al.  Nonalcoholic fatty liver disease , 2005, Canadian Medical Association Journal.

[30]  James G Kench,et al.  Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C , 2003, Hepatology.

[31]  Rocio Lopez,et al.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.

[32]  D. van der Poorten,et al.  Current and novel therapies for the treatment of nonalcoholic steatohepatitis , 2007, Hepatology international.